Eterna Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
ERNA$1.88+2.7%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023
(In thousands, except par value amounts)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $5,116 | $7,575 |
| Other receivables | 351 | 425 |
| Prepaid expenses and other current assets | 697 | 1,599 |
| Total current assets | 6,164 | 9,599 |
| Restricted cash | 4,095 | 4,095 |
| Property and equipment, net | 710 | 493 |
| Right-of-use assets - operating leases | 36,524 | 32,781 |
| Goodwill | 2,044 | 2,044 |
| Other assets | 120 | 120 |
| Total assets | $49,657 | $49,132 |
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,063 | $1,067 |
| Accrued expenses | 1,868 | 1,893 |
| Income taxes payable | 6 | 2 |
| Operating lease liabilities, current | 2,874 | 2,216 |
| Due to related party, current | 768 | 1,205 |
| Deferred revenue, current | 189 | 190 |
| Total current liabilities | 7,768 | 6,573 |
| Convertible notes, net | 8,014 | 6,773 |
| Warrant liabilities | 186 | 116 |
| Operating lease liabilities, non-current | 36,565 | 32,854 |
| Deferred revenue, non-current | 345 | 392 |
| Contingent consideration liability | 107 | 107 |
| Other liabilities | 84 | 84 |
| Total liabilities | 53,069 | 46,899 |
| Stockholders’ (deficit) equity: | ||
| Preferred stock, $0.005 par value, 1,000 shares authorized, 156 designated and outstanding of Series A convertible preferred stock at March 31, 2024 and December 31, 2023, $156 liquidation preference | 1 | 1 |
| Common stock, $0.005 par value, 100,000 shares authorized at March 31, 2024 and December 31, 2023; 5,410 issued and outstanding at March 31, 2024 and December 31, 2023 | 27 | 27 |
| Additional paid-in capital | 190,188 | 189,186 |
| Accumulated deficit | (193,628) | (186,981) |
| Total stockholders’ (deficit) equity | (3,412) | 2,233 |
| Total liabilities and stockholders’ (deficit) equity | $49,657 | $49,132 |
CONDENSED CONSOLIDATEDSTATEMENTS OFOPERATIONS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.